Wednesday February 21st 2018

Disarm Therapeutics Appoints Peter Keller Chief Business Officer

CAMBRIDGE, Mass., Dec. 19, 2017 — (Healthcare Sales & Marketing Network) — Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological diseas… Biopharmaceuticals, Neurology, Personnel Disarm Therapeutics, SARM1, multiple sclerosis, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Follow this link: 

Disarm Therapeutics Appoints Peter Keller Chief Business Officer

Leave a Comment

More from category

MS patients who feel stigmatized more likely to suffer from depression
MS patients who feel stigmatized more likely to suffer from depression

People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, according to [Read More]

Stigma increases risk of depression for people with Multiple Sclerosis
Stigma increases risk of depression for people with Multiple Sclerosis

(Penn State) People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, [Read More]

Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…
Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…

Subtle gait and balance dysfunction is a precursor to loss of mobility in multiple sclerosis (MS). Biomechanical [Read More]

What side effects can result from interferon?
What side effects can result from interferon?

Interferon is used to treat several health conditions, but it has a range of side effects. We look at how these vary in [Read More]

FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS
FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS

Glatopa 40 mg/mL joins already-approved Glatopa 20 mg/mL, a glatiramer acetate generic for treatment of relapsing forms [Read More]